Ajinomoto Cambrooke, Inc.

Ajinomoto Cambrooke, Inc. is a leading company in the field of therapeutic medical nutrition, with a focus on developing improved nutritional therapeutic options for individuals with serious medical disorders. Founded in 2000 by Lynn and David Paolella, the company has a deeply personal motivation, as the parents of two children diagnosed with the rare disease phenylketonuria (PKU). The company pioneers the production of medical formulas and foods for the management of various medical conditions and constantly innovates new nutritional options aimed at a wide array of diseases. One of its notable achievements is being the first medical foods company to launch a natural intact protein for the dietary management of PKU, called Glytactin™ (modified glycomacropeptide). The company also collaborates with academia and industry partners to transform early-phase development projects in therapeutic nutrition into viable commercial products. Focused on patients with rare diseases, Cambrooke employs scientific experts in the development, manufacturing, and commercialization of nutritional therapeutics, with their products being supported by clinical evidence for the nutritional management of medical needs before they are selected for commercialization. In April 2016, Cambrooke received a Series C investment from Seventure Partners, Galen Partners, and Ruffena Capital, demonstrating the confidence and support from prominent investors in the industry. With its commitment to addressing the nutritional requirements of both large and small patient populations, Cambrooke's dedication and innovation in therapeutic medical nutrition make it a compelling venture for further investment and expansion.